MarketInOut Stock Screener Log In | Sign Up
 

Iovance Biotherapeutics Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/07/2026 16:00
Iovance Biotherapeutics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization5,847.86 mln
Float393 mln
Earnings Date11/05/2026

Piotroski F-Score

6 / 9
Solid

Beneish M-Score

-2.39
Borderline

1-Year Forecast

12.80
Fairly priced

Relative Strength

98 / 100
Top performer

Debt / Equity

0.06
Debt-free

Pre-Tax Margin

-90%
Severely loss-making

Business Description

Iovance Biotherapeutics is a California-based company that creates cancer treatments by extracting and multiplying a patient's own immune cells to fight tumors. Its lead product, Amtagvi, is approved for adults with advanced melanoma that has not responded to prior treatment, while Proleukin serves patients with melanoma and kidney cancer. The company has a broad pipeline targeting several other cancers, including cervical, lung, and head and neck cancers, and works alongside major research institutions and pharmaceutical partners to advance its therapies.

Key Fundamentals

EPS-0.69
ROE-40.69
RPS0.79
ROIC-55.99
ROA-31.70
EBITDA, mln-249
EV / EBITDA-25.94
EV / EBIT-21.95
Revenue, mln325
EV / Revenue19.85

Quote Details

Last 12.92
Change -0.04 (-0.31%)
Open 12.52
Volume 14,516,729
Turnover 187,556,144
Average Volume 18,741,904

Financial Ratios

Pre-Tax Profit Margin-90
Leverage Ratio1.24
Current Ratio4.35
Price / Book9.09
Price / Tangible Book14.25
Debt / Equity0.06
Price / Sales18.75

Financial Strength

Altman Z-Score17.21
Piotroski F-Score 6 / 9
Beneish M-Score-2.39
1-Year Target Price12.80
Short Ratio6.01
Short % of Float20.57

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -12.82% 6 / 100   
1 Month 48.51% 99 / 100   
2 Months 225% 100 / 100   
6 Months 272% 99 / 100   
1 Year 485% 100 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us